RBC Capital: Regeneron Pharma (REGN) Could Soar on Eylea Spin
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $943.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


